Supernus
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans op...
Latest News
6 days ago · globenewswire.com
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in LondonROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.
8 days ago · benzinga.com
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
13 days ago · 247wallst.com
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and MoreWall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades landing on names that have struggled all year.
14 days ago · fool.com
Why Indivior Pharmaceuticals Stock Topped the Market TodayThe peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.
18 days ago · seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
18 days ago · zacks.com
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesSupernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.01 per share a year ago.
18 days ago · marketbeat.com
Supernus Pharmaceuticals Q3 Earnings Call HighlightsSupernus Pharmaceuticals NASDAQ: SUPN reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals.
18 days ago · benzinga.com
Supernus Pharmaceuticals Q3 2026 Earnings Call TranscriptSupernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
18 days ago · globenewswire.com
Supernus Announces Third Quarter 2026 Financial ResultsROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2026 and associated Company developments.
19 days ago · prnewswire.com
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Huron Consulting Group Inc. (NASD: HURN) will replace Supernus Pharmaceuticals Inc. (NASD: SUPN) in the S&P SmallCap 600 before the opening of trading on Tuesday, November 3, instead of Monday, November 2. S&P SmallCap 600 constituent Indivior Pharmaceuticals Inc. (NASD: INDV) is acquiring Supernus Pharmaceuticals in a transaction expected to close soon, subject to final closing conditions.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SUPN